Creative Planning
KROS icon

Creative Planning’s Keros Therapeutics KROS Stock Holding History

Creative Planning’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Sell
16,708
-1,099
-6% -$12.2K ﹤0.01% 3907
2026
Q1 		$197K Sell
17,807
-5,324
-23% -$82.2K ﹤0.01% 3744
2025
Q4 		$471K Sell
23,131
-3,442
-13% -$60.4K ﹤0.01% 2894
2025
Q3 		$420K Buy
26,573
+2,347
+10% +$34.7K ﹤0.01% 2865
2025
Q2 		$323K Buy
24,226
+6,948
+40% +$93.8K ﹤0.01% 2838
2025
Q1 		$176K Buy
+17,278
New +$201K ﹤0.01% 3117

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Creative Planning's KROS Position: Q2 2026 in Review

Creative Planning reduced its Keros Therapeutics (KROS) stake by 6.2% in Q2 2026, selling an estimated $12.2K and leaving 16,708 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #3907.

Creative Planning first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $471K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Creative Planning held 16,708 shares of Keros Therapeutics worth $179K as of Q2 2026.
  • Creative Planning sold 1,099 Keros Therapeutics shares in Q2 2026, an estimated $12.2K.
  • Keros Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3907 holding.
  • Creative Planning first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Creative Planning's Keros Therapeutics position peaked at $471K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.